Advertisement
Canada markets closed
  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CAD/USD

    0.7273
    +0.0010 (+0.14%)
     
  • CRUDE OIL

    83.34
    +0.61 (+0.74%)
     
  • Bitcoin CAD

    87,856.59
    +529.27 (+0.61%)
     
  • CMC Crypto 200

    1,375.52
    +62.90 (+4.79%)
     
  • GOLD FUTURES

    2,405.20
    +7.20 (+0.30%)
     
  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     
  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

Nonalcoholic steatohepatitis (or NASH) focused stocks have been garnering more investor interest so far in 2018. In this series, we’ll analyze three companies with focused NASH pipelines: Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), and Madrigal Pharmaceuticals (MDGL).